These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

186 related articles for article (PubMed ID: 31711873)

  • 1. Receipt of opioid agonist treatment halves the risk of HIV-1 RNA viral load rebound through improved ART adherence for HIV-infected women who use illicit drugs.
    Adams JW; Marshall BDL; Mohd Salleh NA; Barrios R; Nolan S; Milloy MJ
    Drug Alcohol Depend; 2020 Jan; 206():107670. PubMed ID: 31711873
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Substance use patterns and HIV-1 RNA viral load rebound among HIV-positive illicit drug users in a Canadian setting.
    Ladak F; Socias E; Nolan S; Dong H; Kerr T; Wood E; Montaner J; Milloy MJ
    Antivir Ther; 2019; 24(1):19-25. PubMed ID: 30230474
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Longitudinal patterns of illicit drug use, antiretroviral therapy exposure and plasma HIV-1 RNA viral load among HIV-positive people who use illicit drugs.
    Liang J; Nosova E; Reddon H; Nolan S; Socías E; Barrios R; Milloy MJ
    AIDS; 2020 Jul; 34(9):1389-1396. PubMed ID: 32590435
    [TBL] [Abstract][Full Text] [Related]  

  • 4. HIV viral suppression and longevity among a cohort of children initiating antiretroviral therapy in Eastern Cape, South Africa.
    Teasdale CA; Sogaula N; Yuengling KA; Wang C; Mutiti A; Arpadi S; Nxele M; Pepeta L; Mogashoa M; Rivadeneira ED; Abrams EJ
    J Int AIDS Soc; 2018 Aug; 21(8):e25168. PubMed ID: 30094952
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Social and environmental predictors of plasma HIV RNA rebound among injection drug users treated with antiretroviral therapy.
    Milloy MJ; Kerr T; Buxton J; Rhodes T; Krusi A; Guillemi S; Hogg R; Montaner J; Wood E
    J Acquir Immune Defic Syndr; 2012 Apr; 59(4):393-9. PubMed ID: 22134149
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Longer duration of homelessness is associated with a lower likelihood of non-detectable plasma HIV-1 RNA viral load among people who use illicit drugs in a Canadian setting.
    Loh J; Kennedy MC; Wood E; Kerr T; Marshall B; Parashar S; Montaner J; Milloy MJ
    AIDS Care; 2016 Nov; 28(11):1448-54. PubMed ID: 27248328
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A simple self-reported adherence tool as a predictor of viral rebound in people with viral suppression on antiretroviral therapy.
    O'Connor JL; Gardner EM; Esser S; Mannheimer SB; Lifson AR; Telzak EE; Phillips AN;
    HIV Med; 2016 Feb; 17(2):124-32. PubMed ID: 26186609
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Younger Age Predicts Failure to Achieve Viral Suppression and Virologic Rebound Among HIV-1-Infected Persons in Serodiscordant Partnerships.
    Mujugira A; Celum C; Tappero JW; Ronald A; Mugo N; Baeten JM
    AIDS Res Hum Retroviruses; 2016 Feb; 32(2):148-54. PubMed ID: 26670218
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Gender differences in HIV-1 RNA rebound attributed to incomplete antiretroviral adherence among HIV-Infected patients in a population-based cohort.
    Kuyper LM; Wood E; Montaner JS; Yip B; O'connell JM; Hogg RS
    J Acquir Immune Defic Syndr; 2004 Dec; 37(4):1470-6. PubMed ID: 15602125
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Plasma HIV-1 RNA viral load rebound among people who inject drugs receiving antiretroviral therapy (ART) in a Canadian setting: an ethno-epidemiological study.
    Small W; Milloy MJ; McNeil R; Maher L; Kerr T
    AIDS Res Ther; 2016; 13():26. PubMed ID: 27462360
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Socioeconomic marginalization and plasma HIV-1 RNA nondetectability among individuals who use illicit drugs in a Canadian setting.
    Richardson LA; Kerr TH; Dobrer S; Puskas CM; Guillemi SA; Montaner JS; Wood E; Milloy MJ
    AIDS; 2015 Nov; 29(18):2487-95. PubMed ID: 26558546
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Time to viral load suppression in antiretroviral-naive and -experienced HIV-infected pregnant women on highly active antiretroviral therapy: implications for pregnant women presenting late in gestation.
    Aziz N; Sokoloff A; Kornak J; Leva NV; Mendiola ML; Levison J; Feakins C; Shannon M; Cohan D
    BJOG; 2013 Nov; 120(12):1534-47. PubMed ID: 23924192
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Linkage and retention in care and the time to HIV viral suppression and viral rebound - New York City.
    Robertson M; Laraque F; Mavronicolas H; Braunstein S; Torian L
    AIDS Care; 2015; 27(2):260-7. PubMed ID: 25244545
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Physician experience and rates of plasma HIV-1 RNA suppression among illicit drug users: an observational study.
    Sangsari S; Milloy MJ; Ibrahim A; Kerr T; Zhang R; Montaner J; Wood E
    BMC Infect Dis; 2012 Jan; 12():22. PubMed ID: 22276960
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Incidences and factors associated with viral suppression or rebound among HIV patients on combination antiretroviral therapy from three counties in Kenya.
    Maina EK; Mureithi H; Adan AA; Muriuki J; Lwembe RM; Bukusi EA
    Int J Infect Dis; 2020 Aug; 97():151-158. PubMed ID: 32497804
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Use of a prescription-based measure of antiretroviral therapy adherence to predict viral rebound in HIV-infected individuals with viral suppression.
    Cambiano V; Lampe FC; Rodger AJ; Smith CJ; Geretti AM; Lodwick RK; Holloway J; Johnson M; Phillips AN
    HIV Med; 2010 Mar; 11(3):216-24. PubMed ID: 20002781
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Alcohol, smoking, recreational drug use and association with virological outcomes among people living with HIV: cross-sectional and longitudinal analyses.
    Jones TPW; Lampe FC; Arenas-Pinto A; Smith C; McDonnell J; Haddow L; Johnson M; Yousef E; Lascar M; Maria Geretti A; Sherr L; Collins S; Phillips AN; Rodger AJ;
    HIV Med; 2022 Mar; 23(3):209-226. PubMed ID: 34634176
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Initiating HCV treatment with direct acting agents in opioid agonist treatment: When to start for people co-infected with HIV?
    Panagiotoglou D; Krebs E; Min JE; Olding M; Ahamad K; Ti L; Montaner JSG; Nosyk B
    Int J Drug Policy; 2017 Sep; 47():169-176. PubMed ID: 28578865
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Improvements in HIV treatment outcomes among indigenous and non-indigenous people who use illicit drugs in a Canadian setting.
    Milloy MJ; King A; Kerr T; Adams E; Samji H; Guillemi S; Wood E; Montaner J
    J Int AIDS Soc; 2016; 19(1):20617. PubMed ID: 27094914
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Uptake and adherence to highly active antiretroviral therapy among HIV-infected people with alcohol and other substance use problems: the impact of substance abuse treatment.
    Palepu A; Horton NJ; Tibbetts N; Meli S; Samet JH
    Addiction; 2004 Mar; 99(3):361-8. PubMed ID: 14982549
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.